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Abstract 
 
Introduction  
Kleine-Levin syndrome (KLS) is a rare disease of unknown aetiology, whose diagnosis may 
be challenging. We aimed to estimate KLS prevalence in French-speaking Switzerland, and 
assess differences with mimicking conditions. 
 
Methods  
In this population-based approach, we contacted Swiss sleep-certified centers and 
neurologists in French-speaking Switzerland, and gathered detailed clinical data from patients 
referred for recurrent hypersomnia or suspected KLS. 
 
Results 
We identified 7 patients with diagnosed KLS (6 since 2009), leading to a prevalence 
estimation of 3.19 per million (95% confidence interval: 1.55-6.59). Median age at diagnosis 
was 17 years (range; 12 - 19), 71.4% of them were men and mean diagnosis delay after the 
first episode was 20.1 ± 10.9 months. We identified 9 mimics patients referred to our center; 
they differed from KLS patients by their higher age at disease onset (median: 15 (range; 12-
16) vs 19 (range; 16-64) years; p<0.001), suspected KLS as referral reason (more frequent in 
mimics, P=0.003), and precipitant factors (more frequent in KLS, P=0.011). Of the mimics 
patients, 77% (versus 28% in KLS) had a psychiatric diagnosis. 
 
Interpretation 
This study suggests a relatively higher KLS prevalence than previously reported. As 
compared to KLS, mimics patients have higher age at symptoms onset, they are more often 
referred for KLS suspicion, and have a higher prevalence of psychiatric disorders.   
 
 
 
Keywords: Comorbidities, KLS mimics, recurrent hypersomnia, sleep, sleepiness 
 
 
 
 
 
 
 
Introduction 
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Kleine-Levin syndrome (KLS) is a rare disease characterized by a minimum of two recurrent 
episodes of hypersomnia, lasting from 2 days to 5 weeks, which recur at least once every 18 
months, and are accompanied by at least one of the following symptoms: cognitive 
abnormalities, altered perception, eating disorder (hyperphagia or anorexia) and disinhibited 
behaviour such as hypersexuality. Between episodes, alertness, behaviour and cognitive 
functions usually become normal.1 Diagnosis requires the exclusion of other disorders, mainly 
psychiatric (such as bipolar psychosis) or sleep related (such as idiopathic hypersomnia or 
narcolepsy). Its diagnosis may be very challenging, as no recognized biological marker has 
been identified.  
 
KLS occurs mainly in young male adolescents and may wean off in adulthood.2 Its 
pathophysiology is still unknown, although according to recent functional-imaging-studies; 
hypothalamus, thalamus, caudate nucleus, angular gyrus, anterior cingulated, dorsomedial 
prefrontal, orbitofrontal and temporal cortices seem to be hypoperfused during episodes.3–8 
Several precipitant factors have been described before occurrence of an episode, among 
which infections, followed by alcohol consumption, sleep deprivation, unusual stress and 
head trauma.2,9–12 A study pointed to a significantly increased HLA-DQB1*0201 allele 
frequency in KLS patients, leading to a possible autoimmune hypothesis, but this has not been 
confirmed in larger cohort.2,13 Actually no placebo-controlled trials concerning treatment 
management are available, although lithium seems to be the most widely assessed 
prophylactic drug for patients with frequent and disabling episodes.2,12,14,15 
 
The prevalence of KLS, classically given at 1 per million,  has been recently evaluated at 1.8 
cases per million in France.9 At our center, we currently follow several KLS patients, 
suggesting a somewhat higher prevalence than described in the literature. Moreover, we also 
ruled out KLS diagnosis in a consistent number of patients in recent years referred for this 
suspicion.  
 
The aim of our study was thus to estimate the prevalence of KLS in the French-speaking part 
of Switzerland, and to characterize the typical clinical presentation of these patients, with the 
purpose to compare it with the presentation of patients with mimicking diagnoses, among 
which KLS was first suspected but finally ruled out. 
Methods 
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Design and Subjects  
Data from all patients referred to our center for recurrent episodes of hypersomnia or 
suspected KLS, identified by AOR and JHR, were retrospectively reviewed between 
November 2006 and August 2015. Additionally, all private-practice neurologists and sleep-
specialists working in certified sleep-centers of the French-speaking part of Switzerland, 
including the Cantons of Vaud, Neuchâtel, Jura, Geneva, Fribourg, Valais (French-speaking 
districts), and Bern (French-speaking districts and Bern-city), were asked if KLS patients 
from the French-speaking side of the country were diagnosed and/or followed. The Vaud 
Cantonal Ethics Committee on research involving humans approved the study.  
 
Data collection 
For patients fulfilling the KLS criteria of the International Classification of Sleep Disorders,1 
we collected data concerning: Demographics, time of first episode, time of diagnosis, number 
and duration of episodes, interval between episodes and since the last relapse, 
pharmacological treatment, precipitant factors, and disease evolution (relapsing remitting vs 
long episodes). We indexed the first symptoms of the disease and the referral reason, the 
presence of hypersomnia (at least in two episodes), cognitive, eating, sexuality-related 
disorders, behavioural or psychological disturbances. We also collected the therapy currently 
used and the presence of comorbidities. For patients referred for suspected KLS but for which 
this diagnosis was not confirmed (“mimics”), we collected the following data: Demographics, 
final diagnosis, precipitant factors, first symptoms of the disease, referral reason, the presence 
of cognitive, eating, sexually-related, behavioural or psychological disturbances, and the 
presence of comorbidities. When available, we also reviewed data from complementary 
investigations, including brain MRI, PET-CT, standard EEG, polysomnographic recordings, 
MSLT, actigraphy, biological measures, lumbal punctures, CSF examination, urine tests and 
Neuropsychological investigations. 
 
Statistical analysis  
Comparisons between groups were performed using Mann-Whitney U tests or two-tailed 
Fisher’s exact tests, as needed. The prevalence was calculated (using the Wilson’s method for 
the confidence interval, in view of the low numbers), using the data provided by the Swiss 
Federal Statistics Office (Federal Statistical Office, Neuchâtel 2015, accessed on September 
28th 2015).16 The number of inhabitants in 2014 (in parentheses) of the Cantons of Fribourg 
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(303.337), Geneva (477.385), Jura (72.410), Neuchâtel (177.327), and Vaud (761.446) were 
included. Concerning the Bern and Valais cantons, only the French-speaking districts were 
considered: Jura-bernois and Biel (151.246) regarding Bern, and Conthey, Entremont, Hérens, 
Martigny, Monthey, Saint-Maurice, Sierre and Sion (249.479) regarding Valais. The total 
number of inhabitants used to calculate the prevalence in the French-speaking Switzerland 
was 2’192’670. We did not correct for multiple comparisons, given the exploratory character 
of this study. Comparisons between prevalence of KLS in French-speaking Switzerland and 
France were assessed using a likelihood ratio χ2 test. 
 
Results  
 
We identified 7 patients with KLS according to the ISCD-3 criteria,1 and 9 mimic cases, 
whose details are summarized in Table 1 and 2. Apart from a patient formerly diagnosed in 
2002, all other subjects were diagnosed since 2009.  
 
Prevalence of KLS 
The estimated prevalence of KLS in the French-speaking part of Switzerland was 3.19 per 
million (95% confidence interval: 1.55-6.59); this was not statistically different from the 1.8 
per million estimation in France (P=0.148). 9 Figure 1 shows the geographical distribution of 
KLS patients; Figure 2 compares the number of KLS patients to the inhabitants of each Swiss 
canton considered in this study. Five subjects were living in the canton of Vaud, and the 
remaining two in Fribourg and Valais. 
 
KLS patients characteristics 
Six patients were diagnosed and followed-up at our center, four young men and two young 
women. One additional man was identified outside our hospital, in Valais. Table 1 shows the 
clinical characteristics of KLS patients. Mean age at diagnosis was 17 years (range; 12 – 19), 
and median age at onset was 15 years (range; 12 – 16). The mean delay to diagnosis after the 
first episode was 20.1 ± 10.9 months, the mean duration of the episodes was 7.42 ± 2.37 days, 
with a median disease-free interval of 2 months (range ; 1 – 35). The reported precipitant 
factors were: influenza-like infection (in four patients), alcohol consumption (in two), and 
long-time video gaming (in one). Two young men presented an unfavourable course, with 
progressively frequent and longer episodes (in one patient, an episode lasted over one year), 
and shorter illness-free intervals. The five other patients experienced a typical relapsing-
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remitting course. One subject was not taking any treatment, one ritaline and lamotrigine, and 
the other five were under lithium (two with additional compounds: escitalopram and 
amantadine in one each); an increase in duration of disease-free intervals were observed in 
three patients taking lithium. We observed one recurrence upon lithium weaning in one of 
them, and in two patients, lithium possibly helped to a remission (in association with 
amantadine in one of them). In one patient, lithium decreased subjectively the severity of the 
symptoms, and in another patient, lithium did not alleviate the symptoms. Psychiatric 
evaluation revealed that two of them had a psychiatric comorbidity, respectively depressive 
and anxiety disorder (Table 2). Extensive complementary investigations were normal or 
showed non-specific abnormalities, and did not enable specific distinction between KLS and 
mimics patients. 
 
Mimics patients and differences with KLS-patients 
Nine patients were detected at our center, four males and five females. Their median age at 
diagnosis was 26 years (range; 17 – 64), and the median age at symptomatology onset was 19 
(range; 16 to 64). In 7/9 (77%) mimic patients, psychiatric diagnoses were retained, which are 
given in Table 2. The definite diagnoses in the two remaining mimic patients were idiopathic 
hypersomnia and a circadian sleep disorder. 
Table 2 highlights differences between KLS and mimics patients. Patients with well-defined 
KLS were referred for suspicion of viral encephalitis or epilepsy, feverish state unknown 
origin, mental slowness, and idiopathic hypersomnia, whereas the majority of mimics patients 
were referred for KLS suspicion. KLS patients had also a younger age than mimics patients 
regarding symptomatology onset. We found only one mimic patient who presented an 
influenza-like infection as precipitant factor. Two reported a psychological stress (sentimental 
rupture, family and work-related stress), the remaining 6 patients reported no specific 
precipitant factors, whereas all KLS patients presented one. Others clinical characteristics, 
including cognitive symptoms, eating-disorders, behavioural disturbances, sexual-related 
disorder, psychological symptoms, did not show any remarkable differences. 
 
 
 
 
 
Discussion 
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This study estimates the prevalence of KLS in the French-speaking part of Switzerland at 3.19 
per million (95% CI: 1.55-6.59), and highlights the differences between defined KLS patients 
and mimics, who tended to be older at disease onset, with no major gender predominance and 
were mainly specifically referred to a specialized center for KLS suspicion. All KLS patients 
presented precipitant factors, while only 3 mimics patients reported one. Symptoms, including 
cognitive and psychological symptoms, eating and sexual-related disorders, and behavioral 
disturbances could be close, although mimics patients seem to present less derealisation, The 
definite diagnosis retained for mimics was a psychiatric disorder.  
 
Our estimated prevalence of KLS seems somewhat higher than previously published data; 1.5 
per million worldwide,14 and 1.8 per million in France,9   a difference that is not statistically 
significant as compared to France. The geographical distribution of KLS patients, and the 
marked overrepresentation of patients from the canton of Vaud (5 out of 7), may suggest that 
this entity could remain underdiagnosed in some areas with limited access to specialized 
centers. We might still have missed some KLS patients, despite contacting all certified sleep 
centers and neurologist in the study region; alternatively, a yet unidentified factor related to 
genetics or exposure could be at play; indeed, KLS prevalence strongly varies across French 
regions.9  
 
The mean latency of diagnosis of the KLS patients in our study (20 month) appears relatively 
shorter than previously described; about 4 years in 2001,17 and 2 years in 2011,11 and 
indicates that increasing KLS awareness, at least in selected centers, may influence this 
aspect. Whether this tendency of higher prevalence as compared to the classically given 
prevalence at 1-1.5 per million reflects a natural fluctuation or is the consequence of increased 
awareness remains to be determined; the fact that in our study 6 out of 7 patients have been 
diagnosed after 2009 favors the second hypothesis. 
 
The clinical presentation of KLS patients may be difficult to distinguish from mimics. Our 
study shows that mimics are mostly related to various psychiatric disorders. Marked 
differences between KLS patients and mimics cases were observed in the referral reasons: 
while KLS patients had a suspicion of viral encephalitis, epilepsy, mental slowness or 
hypersomnia, the majority of mimics patients were specifically referred for KLS suspicion. 
This underscores the need for patients with KLS suspicion to undergo a formal neurologic 
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and a psychiatric interview as pointed out recently.9 KLS patients had also younger age at 
symptoms onset, a predominance of males, and the age at disease onset in our cohort is 
similar to previously reported cases.2,11,12,14 This underlines the fact that KLS is 
predominantly an adolescent-onset disease, and adult-onset is much less frequently 
observed.12,14,18 KLS and mimics patients also differed according to events associated with 
disease onset: all KLS patients reported precipitant factors, among them a majority of 
influenza-like infection, versus only 3 mimics patients. This significant difference should be 
viewed cautiously, since a minority of KLS patients reported in the literature did not 
remember precipitant events.2,14 Finally, it is interesting to note that in our center mimic 
patients outnumbered KLS patients, as opposed to a recent French nationwide publication.9 
This may reflect a referral bias or a geographical specific characteristic, but may be of interest 
for practicing sleep specialists and neurologists.  
 
All KLS patients described cognitive impairment, but none reported sexual-related disorders; 
a minority had ictal megaphagia, or appetite loss. This emphasizes the importance of the 
cognitive disorders, specifically derealisation, as one of the core symptoms of KLS, and that 
sexual-related disorders seem only inconstantly found.2,9–12  
 
Concerning treatment, five KLS patients were currently taking lithium and all reported 
improvement, with longer disease-free interval in four. Two of them reported no more 
episodes, since respectively 40 and 11,5 months until August 2015. In one patient, a 
recurrence was observed upon progressive lithium weaning, and a favourable therapeutic 
response was obtained after lithium increase, as previously reported.2,12,14,15 In two patients, 
an unfavourable course was observed: their episodes became more frequent and longer, 
merging into them with shorter illness-free intervals. This evolution course seems to be more 
frequent than previously described, also in the light of a recent study with a large cohort of 
KLS patients, 9 and challenges the idea that KLS is a “benign” disease.  
 
To the best of our knowledge, this is the first population-based study assessing KLS 
prevalence not only in Switzerland, but outside France9 (and besides one worldwide 
estimation from previously published cases14 ). The characterisation of clinical presentations 
and course of KLS provides clues to differentiate defined KLS patients and potentially 
mimics patients. However, we acknowledge potential limitations. Its retrospective design 
prevented an optimal data ascertainment in each patient, and the diagnostic workup was not 
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uniform. The sample size was also relatively small and we could not find many statistically 
significant differences. It is possible that not all the KLS patients in the French-speaking 
Switzerland could be identified despite our efforts. Finally, while we used a population-based 
approach regarding KLS patients, mimics patients were only recruited in our center.  
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FIGURE 1. Geographical location of identified patients with Kleine-Levine syndrome (each point 
represent one patient); the darker coloration represents the French-speaking area of Switzerland. Map 
built with the help of  2015 Geobasis-DE/BKG (2009), Google, https://www.google.ch/maps. 
 
  
 
 
 
 
FIGURE 2. Comparison between number of KLS patients (from 1 to 10, left axis, grey) reported in every 
considered canton and total population of these cantons (in thousands, right axis, black). *Regarding the 
Canton of Valais, only the population currently living in the French-speaking districts was considered. 
**Concerning the Canton of Bern, only the population currently living in the French-speaking districts 
was considered.  
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Table 1. Clinical characteristics, therapy and comorbidities of KLS patients (n=7)      
Patient Age Gender Delay to 
diagnosis 
(Months) 
Number 
of 
episodes 
Episodes 
duration 
(days) 
Interval 
between 
episodes 
(months) 
Precipitant 
factors  
(at minimum 
1 episode) 
Disease 
course Therapy at 08.2015 Tried therapy Improvement with therapy Time since last 
episode 
(08.2015) 
Comorbidities 
1 24 M 4 >> 40  10 2 Influenza-like 
infection fluctuating with chronicization  Lithium Escitalopram Carbamazepine Valproic acid  
Acebutolol 
Melatonin 
Modafinil  
Lamotrigin 
Amantadin  
Zolpidem 
Venlafaxine 
 
Increase 
disease-free 
interval 
< 1 month Depressive 
disorder 
2 22 M 17 10 5-10  6-35  alcohol 
consumption Relapsing-remitting Lithium Modafinil Increase disease-free 
interval ; 
recurrence 
upon lithium 
weaning 
3 months Migraine without 
aura  
3 22 F 30 5 10 12 alcohol 
consumption Relapsing-remitting Lithium Modafinil Possibly helps to a remission ; 
Undergoing 
lithium 
weaning 
40 months Anxiety disorder 
coeliac disease 
4 22 M 37 >23 4-7 1.5 Longtime 
video-gaming fluctuating with chronicization  Lithium Amantadin Lamotrigin 
Modafinil 
Zolpidem  
Subjective 
decrease  
severity of 
symptoms 
Chroniciza-
tion None 
5 19 M 21 14 3-4 6 Influenza-like 
infection Relapsing-remitting Lithium Amantadine - Increase disease-free 
interval and 
possibly helps 
to a remission 
11,5 months None 
6 18 F 20 26 7 1 Influenza-like 
infection Relapsing-remitting Lamotrigin, Ritaline Lithium Modafinil 
Zolpidem 
None < 1 month None 
7 17 M 12 10 7-10 1 Influenza-like 
infection Relapsing-remitting None - None 2 months Acute lymphoblastic 
leukemia in 
childhood 
Mean ± 
SD or 
Median 
with 
range  
  20.14 ± 
10.95 10  (range ; 5 
to 40) 
7.42 ± 
2.37 2  (range ;1 
to 35)  
       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2. Comparison between Kleine-Levin and mimic patients, regarding clinical characteristics. 
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 KLS patients (n=7) Mimics patients (n=9) p value 
Age at symptoms onset (range; 
years) 
 15 (range ; 12 – 16) 19 (range ; 16 – 64) 0.001 
Male gender 5/7 (71.42 %) 4/9 (44.5 %) 0.35 
Referral reason - 2 suspicion of viral encephalitis 
- 1 feverish state unknown origin 
- 1 epilepsy suspicion  
- 1 mental slowness  
- 2 idiopathic hypersomnia 
- 7 KLS suspicion 
- 1 recurrent idiopathic hypersomnia 
- 1 sleep disorder in relation with increased  
djwork rhythm and heartache 
0.003 (for 
referral of 
suspected 
Kleine-Levin) 
Precipitant factors (at 
minimum 1 episode) 
7/7 (100%) 3/9 (33.4 %) 0.011 
Cognitive symptoms 7/7 (100%) 8/9 (88.8 %) 1.000 
Derealisation 6/7 (85.71 %) 3/9 (33.4 %)  
Attention/concentration deficits 6/7 (85.71 %) 6/9 (66.7 %)  
Memory deficits  3/7 (42.85 %) 5/9 (55.6 %)  
Amnesia 5/7 (71.42 %) 3/9 (33.4 %)  
Eating disorders 5/7 (71.42 %) 5/9 (55.6 %) 0.816 
Megaphagia 3/7 (42.85 %) 4/9 (44.5 %)  
Decrease of appetite  2/7 (28.57 %) 1/9 (11.2 %)  
Behavioral Disturbances 4/7 (57.14%) 8/9 (88.8 %) 0.261 
Regression 1/7 (14.28%) 1/9 (11.2 %)  
Inappropriate behavior 2/7 (28.57 %) 0  
Irritability 3/7 (42.85 %) 7/9 (77.8%)  
Impaired speech 1/7 (14.28%) 0  
Sexual-related disorder    
Hypersexuality 0  3/9 (33.4%) 0.213 
Psychological symptoms 5/7 (71.42 %) 6/9 (66.7 %) 1.000 
Psychomotor slowing-down 2/7 (28.57 %) 1/9 (11.2 %)  
Hypothymia  4/7 (57.14%) 4/9 (44.5 %)  
Anxiety 1/7 (14.28%) 5/9 (55.6 %)  
Psychiatric comorbidities 2/7 (28.57 %) 7/9 (77.8%) 0.126 
Depressive disorders  1/7 (14.28%) 4/9 (44.5 %)  
Anxiety disorders 1/7 (14.28%) 2/9 (22.3%)  
Bipolar disorder 0 1/9 (11.2 %)  
Borderline disorder 0 1/9 (11.2 %)  
Mental anorexia  0 1/9 (11.2 %)  
OCD 0 1/9 (11.2 %)  
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